Its medicines are better known than its name. CEO Osamu Okuda explains how a unique strategic alliance, a technology-driven approach to drug discovery, a rigorous focus on quality, and a growing U.S. presence have positioned Chugai for co-creation on a global scale.

Doctors across the United States prescribe medicines that originated in Chugai Pharmaceutical’s laboratories. Hospitals stock them. The medicines are familiar within their therapeutic categories; the company behind them, for the most part, is not.

At the 2026 J.P. Morgan Healthcare Conference, Chugai President and CEO Osamu Okuda described that gap without complaint. If a medicine reaches patients and its value is understood, he considers that a source of pride. The corporate name is secondary to the work.

That modest profile should not be mistaken for limited scale. As of May 29, 2026, Chugai was the largest pharmaceutical company in Japan by market capitalization, at approximately US$83 billion, and ranked among the world’s top 20 pharmaceutical companies by market value.

In a July interview at Chugai’s Tokyo headquarters, that restraint is characteristic. Okuda lowers the temperature before answering. But restraint is not hesitation. Rather than reciting strengths, he defines them—what kind of company Chugai is, and what it chooses to compete on. He qualifies claims that could sound grander than he intends and redirects credit toward the company’s researchers. Later, when a phrase about startups risks suggesting hierarchy, he stops, laughs, and corrects it: Not from above. Together. The ambition is large; his register is quiet—and quietly confident.

But the name matters for what comes next. Drug discovery is too varied and complex for any company to succeed alone. Chugai wants scientists, biotechnology founders and academic researchers to understand its capabilities—and sometimes to make the first call. Recognition, in that sense, is not fame. It is infrastructure for collaboration.

Entering its second century, Chugai’s outward turn is also a return to its beginnings.

A Japanese Company With An Unusual Engine

Chugai was founded in 1925 by Juzo Ueno, after medicine shortages compounded the suffering caused by the Great Kanto Earthquake. He began by importing medicines into Japan. But the name he chose held a larger ambition.

Chugai evokes inside and outside. Medicines came in from abroad; one day, Ueno hoped, medicines made in Japan would travel out to the world.

A century later, that movement has become the company’s operating reality.

Yet Chugai remains compact by global pharmaceutical standards: 7,872 employees at the end of 2025. Okuda is plain about what that means—not a limitation, but a definition of the game Chugai plays. “We don’t compete on scale,” he says. “We build on our unique science and technology to take on drug discovery challenges that are distinctly ours.”

In 2002, Chugai began a strategic alliance with Roche. Roche became the majority shareholder, but Chugai remained publicly listed, retained autonomous management and continued to set its own research priorities.

The exchange ran in both directions. Chugai could bring Roche-originated medicines to patients in Japan; medicines originating at Chugai could reach global markets through Roche’s network.

That exchange did two things at once. First, access to Roche’s portfolio in Japan created a stable revenue base. Chugai’s researchers gained room to pursue difficult, long-horizon work without constant pressure to produce the company’s next source of revenue. Second, global development through Roche imposed a formidable test: Chugai had to produce work that a global pharmaceutical leader considered genuinely worth advancing.

That freedom shaped a distinctive identity. Chugai practices technology-driven drug discovery: it builds proprietary platforms first, then pursues the diseases they unlock. The approach has produced a series of antibody-engineering firsts—bispecific antibodies engineered to perform the function of a missing clotting factor in hemophilia A, recycling antibodies designed to bind their targets again and again—technologies that turned previously impossible medicines into approved ones. Having now established macrocyclic peptides as a proprietary drug discovery platform, that engine is the source of the company’s competitiveness, the reason behind its global track record—and the foundation of what it offers the partners it now seeks.

The alliance did not remove competitive pressure. It changed its horizon: short-term survival pressure became a long-term quality bar.

The results are striking for a company of Chugai’s size. In 2025, Chugai generated US$7.9 billion in revenue (1.26 trillion yen), with a core operating margin of 49.5%. According to the company, since 2010 Chugai has commercialized eight global products and earned nine FDA Breakthrough Therapy Designations. And behind those figures lies the outcome Okuda values most: Chugai-discovered medicines approved in more than 110 countries, reaching patients around the world.

Those figures establish credibility. But the more revealing story is the choices behind them.

Quality Is A Management Decision

Chugai calls its approach Quality-Centric Drug Discovery. The phrase can sound like familiar corporate language until Okuda explains what it demands in practice.

Before a candidate is selected for advancement toward clinical development, Chugai’s teams narrow their options to the molecule they believe is most strongly differentiated across biological activity, safety, metabolism, stability and the other properties that determine whether a scientific idea can become a viable medicine. According to the company’s 2026 J.P. Morgan Healthcare Conference presentation, every Chugai-discovered molecules that have reached Phase 3—final-stage human trials—for their first indication have successfully completed that stage; industry-wide, roughly three in 10 fail there.

That record is not simply good fortune at the finish line. It reflects a harder filter applied years earlier.

Quality-centric discovery is also an investment discipline. The questions are basic but difficult: Is there a genuine patient need? Can the concept meet it? And is it supported by scientific data? If so, the project can move forward. At this early stage—before Phase 1—commercial potential is difficult to forecast. Okuda says Chugai therefore does not base the decision primarily on projected sales or price. Here, “value” means value for patients.

Conviction, however, is not permission to continue indefinitely.

In July 2025, Chugai collectively discontinued five projects in early-stage in-house clinical development after reviewing the available data and the overall portfolio. Okuda did not characterize them as hopeless; with more time, some might have succeeded. But resources tied to lower-priority programs are unavailable to stronger or earlier opportunities. Stopping those projects allowed the company to concentrate its people and capital on a smaller, higher-quality pipeline.

The discipline works in both directions. Patient need establishes the purpose. Data determines the next step. Management protects the ability to follow both.

Partnering Without Hollowing Out

For much of its history, Chugai’s innovation was driven primarily by internal research and development. That approach produced important results. It also has limits that have become harder to ignore.

Gene and cell therapies, nucleic-acid medicines, new kinds of small molecules, digital tools and other emerging technologies are advancing too quickly for any one organization to master them all. A company can build genuine depth in a few areas, Okuda argues, but not in every promising field. Remaining entirely within its own walls would make it harder to remain competitive.

Its answer is open innovation, although Okuda uses the term carefully. Chugai’s preferred model is not simply to purchase a finished technology, absorb it and turn it into another business unit. It may license outside technology, but the objective is to combine it with Chugai’s own capabilities and create something neither side could have made alone.

That places an obligation on Chugai. Open innovation works only if the company continues strengthening its internal science. “No one wants to partner with a company whose technology is stale,” Okuda says. “Cutting-edge technology is what draws people in.” Partnering must extend internal strength, not replace it.

Chugai has begun putting that philosophy into physical form in the United States—and quickly. Established in the Boston area in 2023, the US$200 million Chugai Venture Fund began full-scale operations the following January. On the West Coast, a Partnering Office opened in South San Francisco in January 2026 to build networks with academia, venture investors and biotechnology companies.

These are new footholds, but their direction is clear. Chugai is not waiting for outside discoveries to arrive fully formed. It wants to engage early, while technologies and relationships can still be shaped through co-creation.

This is what Okuda means by the power to connect. A small company cannot possess every capability it needs. But connect its scientists with the right people, technologies, and ideas, he argues, and its capacity can become two, three, five, even 10 times greater. The test is whether the multiplication works in both directions.

“What matters is how we look from the other side of the table,” Okuda says. “You can never be self-satisfied.”

Partners should gain scientific reach, development experience and a path toward patients; Chugai should gain capabilities it does not have and ideas it might not have conceived on its own. Neither side should be merely a resource for the other. Chugai is looking for partners who share its commitment to creating medicines for patients. That requires more than compatible technology. It requires integrity in how the work is conducted, rigor in the science and honesty in the relationship.

That is the proposition Chugai is bringing to the U.S. biotechnology community: distinctive internal science without the assumption that every useful idea must originate inside its own walls. It is not asking partners to feed technology into a finished machine. It is asking whether two sets of capabilities can produce something neither could create alone.

For Okuda, the desired outcome is not simply a successful transaction. It is new value for patients, created by people who trust one another enough to do difficult work together. Technical fit, in his view, is only the starting point: what Chugai seeks are partners who share its values—the same integrity, and the same aspiration to change patients’ lives.

His final invitation is correspondingly direct.

“If you’re interested,” he says, “get in touch.”